|
LARS2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.49779999994537E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.39169999999489E-06 |
| Normal-vs-Stage2 |
8.605800E-01 |
| Normal-vs-Stage3 |
1.68079999918191E-08 |
| Normal-vs-Stage4 |
1.07700000029354E-08 |
| Stage1-vs-Stage2 |
8.503700E-03 |
| Stage1-vs-Stage3 |
2.904400E-02 |
| Stage1-vs-Stage4 |
1.322190E-02 |
| Stage2-vs-Stage3 |
5.031700E-04 |
| Stage2-vs-Stage4 |
1.417700E-04 |
| Stage3-vs-Stage4 |
4.371400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.86190000376286E-08 |
| Normal-vs-AfricanAmerican |
3.803300E-03 |
| Normal-vs-Asian |
1.616670E-03 |
| Caucasian-vs-AfricanAmerican |
2.985600E-01 |
| Caucasian-vs-Asian |
3.650600E-01 |
| AfricanAmerican-vs-Asian |
9.421000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.45350000005473E-06 |
| Normal-vs-Female |
1.93457999999591E-05 |
| Male-vs-Female |
2.051200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.05730000002458E-06 |
| Normal-vs-Age(41-60Yrs) |
1.61616999999614E-05 |
| Normal-vs-Age(61-80Yrs) |
8.775300E-04 |
| Normal-vs-Age(81-100Yrs) |
7.543800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.929200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.202600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.327800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.022400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.676600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.282200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.205700E-02 |
| Classical-VS-Follicular |
9.656300E-03 |
| Classical-VS-Other |
3.267600E-01 |
| Classical-VS-Normal |
2.29820000030578E-07 |
| Tall-VS-Follicular |
4.02800000000036E-05 |
| Tall-VS-Other |
7.395200E-01 |
| Tall-VS-Normal |
3.59799999793964E-08 |
| Follicular-VS-Other |
1.427780E-01 |
| Follicular-VS-Normal |
1.109760E-01 |
| Other-VS-Normal |
4.498800E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.387600E-04 |
| Normal-vs-N1 |
6.00950000873013E-09 |
| N0-vs-N1 |
9.957700E-04 |
|
|
